4554
Fuji Pharmaceutical Industries Co., Ltd.
2026/02/05
The cumulative net sales for the second quarter of the fiscal year ending September 2026 have been revised upward by 1.3% from the previous forecast to JPY 29,420 million, and operating income by 47.0% to JPY 4,100 million. Conversely, net income attributable to owners of parent has been revised downward by 55.4% to JPY 860 million due to the recording...
